Phase II Trial of Canakinumab in High-Risk Former Smokers Launched
A phase II trial is underway to evaluate canakinumab's effects on former smokers at increased cancer risk.
Therapeutic Area
Therapeutic area intelligence for IL-1 Inhibition with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.